|
|
Novel therapies
|
|
|
|
Novel Approaches to Modify Lipids and Lipoproteins
|
|
|
|
Statin Prescription in the UK
|
|
|
|
Percentage of the UK-population
|
|
|
|
All-Cause Mortality in the UK
|
|
|
|
New Approaches to LDL Reduction
|
|
|
|
New Approaches to LDL Reduction
|
|
|
|
Heterozygous Familial Hypercholesterolemia
|
|
|
|
Mipomersen Significantly Reduced LDL-C
|
|
|
|
Distribution of LDL-C %
|
|
|
|
MTPIs – Efficacy comes
|
|
|
|
AEGR 733 HoFH Phase II Study Design
|
|
|
|
Change in Lipids Using Lomitapide
|
|
|
|
HoFH Phase 3: 6-Month Lipid Efficacy
|
|
|
|
LDL Receptor Function and Life Cycle
|
|
|
|
The Role of PCSK9
|
|
|
|
Impact of an Anti-PCSK9
|
|
|
|
Study Design REGN727
|
|
|
|
Changes in LDL-C
|
|
|
|
Change in Calculated LDL-C
|
|
|
|
Attainment of Prespecified LDL-C
|
|
|
|
Novel Approaches to Modify Lipids
|
|
|
|
New Approaches for Raising HDL
|
|
|
|
The Dal-HEART Program
|
|
|
|
25
|
|
|
|
Effects on LDL-C and HDL-C
|
|
|
|
Adjudicated CV Events and Death
|
|
|
|
Adjudicated CV Events and Death
|
|
|
|
Future
|
|
|
|
New Approaches for LDL and HDL
|
|
|
|
ApoA1 Based Therapies
|
|
|
|
New Approaches for Reduction of TG
|
|
|
|
Conclusion
|
|
Download as PPT (PPTX 13.2MB)
Share this page with your colleagues and friends: